Pindolol augmentation enhances response outcomes in first depressive episodes
Por:
Portella, MJ, de Diego-Adelino, J, Puigdemont, D, Perez-Egea, R, Alvarez, E, Artigas, F, Perez, V
Publicada:
1 jul 2009
Resumen:
Effectiveness of Pindolol addition to SSRIs is stilt a matter of debate. Recently, Geretsegger et at. [Geretsegger, C., Bitterlich, W., Stelzig, R., Stuppaeck, C., Bondy, B. and Aichhorn, W. (2008) Paroxetine with Pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients. Eur. Neuropsychopharmacol. 18, 141-146.] have found that never-medicated depressed patients showed a significant sustained response with Paroxetine + Pindolol treatment. Also, patients with a first depressive episode displayed a trend for higher sustained response rates with Pindotol co-administration. Re-anatysing the data of a previous clinical trial of Ftuoxetine + Pindotot [Perez, V., Gitaberte, I., Faries, D., Alvarez, E. and Artigas, F (1997). Randomised, double-blind, placebo-control led trial of Pindolol in combination with Ftuoxetine antidepressant treatment. Lancet 349, 1594-1597.], we have found that first depressive episodes are associated with a significant higher percentage of sustained responses when administering Ftuoxetine + Pindolol (70.3%) compared to Ftuoxetine + Placebo (44%). Moreover, based on a survival analysis, among the patients with a first depressive episode, those who received Ftuoxetine + Pindolol achieved a sustained response significantly earlier (19 days) than those on Fluoxetine + Placebo (35 days). Interestingly, none of these effects were observed in the subsample of recurrent patients. The results suggest that Pindolol augmentation accelerates and enhances the action of SSRI at the beginning of the illness. (C) 2009 Elsevier B.V. and ECNP. AR rights reserved.
Filiaciones:
Portella, MJ:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Psychiat, E-08193 Barcelona, Spain
de Diego-Adelino, J:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Psychiat, E-08193 Barcelona, Spain
Puigdemont, D:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Psychiat, E-08193 Barcelona, Spain
Perez-Egea, R:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Psychiat, E-08193 Barcelona, Spain
Alvarez, E:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Psychiat, E-08193 Barcelona, Spain
Artigas, F:
CIBERSAM, CSIC, Inst Invest Biomed Barcelona, Dept Neurochem & Neuropharmacol,IDIBAPS, Madrid, Spain
Perez, V:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Psychiat, E-08193 Barcelona, Spain
|